KRT88P and hepatitis A virus infection: In 2019, a report from Hong Kong also evaluated long-term post-transplant outcomes of liver transplantations from 461 anti-HBc antibody-positive and 548 anti-HBc antibody-negative donors and showed that there was no difference in long-term prognosis, that de novo hepatitis observed in 3 of the 108 anti-HBc antibody-negative recipients all occurred during the time when lamivudine was used, and that such instances have recently been nearly eliminated [55].